brand logo

Am Fam Physician. 2007;75(1):56-63

A more recent article on lung cancer is available.

Patient information: See related handout on smoking cessation.

Author disclosure: Nothing to disclose.

Lung cancer is the leading cause of cancer-related death in the United States, with an average five-year survival rate of 15 percent. Smoking remains the predominant risk factor for lung cancer. Lung cancers are categorized as small cell carcinoma or non–small cell carcinoma (e.g., adenocarcinoma, squamous cell carcinoma, large cell carcinoma). These categories are used for treatment decisions and determining prognosis. Signs and symptoms may vary depending on tumor type and extent of metastases. The diagnostic evaluation of patients with suspected lung cancer includes tissue diagnosis; a complete staging work-up, including evaluation of metastases; and a functional patient evaluation. Histologic diagnosis may be obtained with sputum cytology, thoracentesis, accessible lymph node biopsy, bronchoscopy, transthoracic needle aspiration, video-assisted thoracoscopy, or thoracotomy. Initial evaluation for metastatic disease relies on patient history and physical examination, laboratory tests, chest computed tomography, positron emission tomography, and tissue confirmation of mediastinal involvement. Further evaluation for metastases depends on the clinical presentation. Treatment and prognosis are closely tied to the type and stage of the tumor identified. For stages I through IIIA non–small cell carcinoma, surgical resection is preferred. Advanced non–small cell carcinoma is treated with a multimodality approach that may include radiotherapy, chemotherapy, and palliative care. Chemotherapy (combined with radiotherapy for limited disease) is the mainstay of treatment for small cell carcinoma. No major organization recommends screening for early detection of lung cancer, although screening has interested researchers and physicians. Smoking cessation remains the critical component of preventive primary care.

Lung cancer is the leading cause of cancer-related death in the United States. In 2006, the disease caused over 158,000 deaths—more than colorectal, breast, and prostate cancers combined.1 Although death rates have begun to decline among men in the United States, the lung recently surpassed the breast as the most common origin of fatal cancer in women.2 Because one fourth of adults smoke, lung cancer will remain a problem for many years.2 Despite advances in lung cancer therapy, the average five-year survival rate is only 15 percent.3 Adenocarcinoma has surpassed squamous cell carcinoma as the most common histologic type of lung carcinoma,4,5 and early metastasis has become increasingly common.

Clinical recommendationEvidence ratingReferences
Patients with central lung tumors should undergo flexible bronchoscopy.C27,28
Patients with peripheral lung tumors who are not surgical candidates should undergo transthoracic needle aspiration.C27,28
Patients undergoing mediastinal staging for lung cancer should receive chest computed tomography plus positron emission tomography.C34,35
There is insufficient evidence to recommend for or against routine screening for lung cancer.C4042
For lung cancer prevention, smokers should be offered nicotine replacement therapy, bupropion (Wellbutrin), nortriptyline (Pamelor), and counseling for smoking cessation.A5053

Risk Factors

Smoking is the predominant risk factor for lung cancer (relative risk [RR] = 10 to 30 compared with nonsmokers)3,6; smoking is directly linked to lung cancer in 90 percent of women and 79 percent of men.7 Secondhand smoke exposure is also a risk factor.8,9 Approximately 3,000 adults die each year from exposure to secondhand smoke, with a dose-response relationship between duration and intensity of exposure.10,11

The most common occupational risk factor for lung cancer is exposure to asbestos (RR = 6)7; the RR for smokers who are exposed to asbestos approaches 60.12 Other common occupational and environmental causes of lung cancer include exposure to radon, arsenic, chromium, nickel, vinyl chloride, and ionizing radiation.13 Preexisting nonmalignant lung diseases, such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and tuberculosis also are associated with increased lung cancer rates.

Pathology

To facilitate treatment and prognostic decisions, lung cancer is categorized as small cell carcinoma or non–small cell carcinoma. Light microscopy is used to further differentiate lung cancer into four major and several minor histologic classes (Table 114,15 ).16 The major histologic classes are adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and large cell carcinoma.

ClassPrevalence (%)Subtypes
Adenocarcinoma40Acinar, bronchioalveolar, papillary, solid carcinoma with mucus formation, mixed
Squamous cell carcinoma25
Small cell carcinoma20Pure small cell carcinoma, combined small cell carcinoma
Large cell carcinoma10Large cell neuroendocrine, basaloid, lymphoepithelial-like, large cell with rhabdoid phenotype
Adenosquamous carcinoma< 5
Carcinoid< 5
Bronchial gland carcinoma< 5

Adenocarcinomas are histologically heterogeneous peripheral masses that metastasize early, and often occur in patients with underlying lung disease.17 Squamous cell carcinomas typically are centrally located endobronchial masses that may present with hemoptysis, postobstructive pneumonia, or lobar collapse. Unlike adenocarcinomas, squamous cell carcinomas generally metastasize late in the disease course.

Small cell carcinomas are clinically aggressive; are usually centrally located with extensive mediastinal involvement; and are associated with early extrathoracic metastases, including paraneoplastic syndrome. Despite their responsiveness to chemotherapy, small cell carcinomas often are advanced at the time of diagnosis, and patients have a poor prognosis.19

Large cell carcinomas are poorly differentiated. These tumors are large peripheral masses associated with early metastases.17

Clinical Presentation

Although approximately 10 percent of lung cancers in asymptomatic patients are detected on chest radiographs, most patients are symptomatic when diagnosed.19 Patients may present with the nonspecific systemic symptoms of fatigue, anorexia, and weight loss, or with direct signs and symptoms caused by the primary tumor or intrathoracic or extrathoracic spread (Table 220 ). A minority of patients present with paraneoplastic syndromes.

Primary tumor
Chest discomfort
Cough
Dyspnea
Hemoptysis
Intrathoracic spread
Chest wall invasion
Esophageal symptoms
Horner syndrome
Pancoast's tumor
Phrenic nerve paralysis
Pleural effusion
Recurrent laryngeal nerve paralysis
Superior vena cava obstruction
Extrathoracic spread
Bone pain, fracture
Confusion, personality change
Elevated alkaline phosphatase level
Focal neurologic deficits
Headache
Nausea, vomiting
Palpable lymphadenopathy
Seizures
Weakness
Weight loss

PRIMARY TUMOR

Chest discomfort, cough, dyspnea, and hemoptysis are common manifestations of a primary tumor. Cough secondary to an endobronchial mass or postobstructive pneumonia occurs in up to 75 percent of patients.20 Dyspnea occurs in up to 60 percent of patients and may be caused by a tumor occluding the airway.20 Intermittent, aching chest discomfort occurs in approximately 50 percent of patients at diagnosis.20 Hemoptysis is found in up to 35 percent of patients with symptoms from a primary tumor.20 Although acute bronchitis is the most common cause of hemoptysis, lung cancer should be suspected in patients older than 40 who present with hemoptysis.20

INTRATHORACIC SPREAD

Forty percent of patients diagnosed with lung cancer initially present with signs and symptoms of intrathoracic spread. Intrathoracic spread is caused by direct extension of the tumor or lymphangitic spread.

Hoarseness from recurrent laryngeal nerve paralysis occurs in 2 to 18 percent of patients.20 Phrenic nerve paralysis may present with dyspnea or an elevated left hemidiaphragm on a chest radiograph.20 A superior pulmonary sulcus tumor (Pancoast's tumor) may present with Horner syndrome and is characterized by a brachial plexopathy and pain along the involved nerve roots.21 Chest wall invasion often presents with persistent, pleuritic pain. Pleural effusions may present with dyspnea, decreased breath sounds, and dullness to percussion.22 Esophageal obstruction may cause dysphagia. Superior vena cava obstruction is characterized by facial swelling and plethora and by dilated veins on the upper torso, shoulders, and arms.23 Although pericardial involvement often is found at autopsy, patients seldom present with symptomatic pericardial effusion or tamponade.24

EXTRATHORACIC SPREAD

Nearly one third of patients with lung cancer present with signs and symptoms of extrathoracic spread.20 Common metastatic sites include bones, liver, adrenal glands, lymph nodes, brain, and spinal cord.

Nonspecific symptoms of extrathoracic spread include weakness and weight loss. Bone metastasis often presents with pain, fracture, or elevated alkaline phosphatase level and usually involves the long bones or vertebrae. Palpable lymphadenopathy, particularly in the supraclavicular fossa, suggests metastasis. Ten percent of patients present with brain metastasis heralded by headache, nausea, vomiting, focal neurologic deficits, seizures, confusion, or personality changes.25 Although liver involvement is common, transaminase elevation is relatively rare.

PARANEOPLASTIC SYNDROMES

Approximately 10 percent of patients with lung cancer develop systemic symptoms related to paraneoplastic syndromes. This is caused by the release of bioactive substances produced by the tumor or in response to the tumor. Symptoms may precede the diagnosis, appear late in the disease course, or suggest recurrence.

Common endocrine syndromes include hypercalcemia, syndrome of inappropriate antidiuretic hormone, and Cushing's syndrome. Digital clubbing and hypertrophic pulmonary osteoarthropathy are common skeletal manifestations. Less well-defined neurologic syndromes include Lambert-Eaton myasthenic syndrome, peripheral neuropathy, and cortical cerebellar degeneration.26

Diagnosis

TISSUE DIAGNOSIS

There are a variety of techniques to assist physicians in obtaining an accurate tissue diagnosis (Table 327 ). Selecting the most appropriate test usually requires consultation with a pulmonologist, interventional radiologist, or thoracic surgeon. In patients with apparent early non–small cell carcinomas, who are surgical candidates, thoracotomy is the recommended test for tissue diagnosis and staging. In patients with presumed small cell or metastatic non–small cell carcinomas, the diagnosis should be made using the most convenient and least invasive method available (e.g., thoracentesis of a pleural effusion, excisional biopsy of an accessible node, bronchoscopy, transthoracic needle aspiration).27

Diagnostic methodSensitivity (%)Specificity (%)IndicationComments
Sputum cytology (at least three specimens)Central tumors: 7199Central tumor and hemoptysisNoninvasive; further testing needed after negative result
Peripheral tumors: < 50
Thoracentesis80> 90Pleural effusion
Excisional biopsy of an accessible nodePalpable lymphadenopathy
Flexible bronchoscopy with or without transbronchial needle aspirationCentral tumors: 8890Central or peripheral tumor and mediastinal lymphadenopathyFluoroscopic or CT guidance; transbronchial needle aspiration improves sensitivity in peripheral tumors
Peripheral tumors: 60 to 70
Transthoracic needle aspirationPeripheral tumors: 9097Peripheral tumor in nonsurgical candidates or when transbronchial needle aspiration is inconclusiveFluoroscopic or CT guidance; the assistance of a cytopathologist improves diagnostic yield
Video-assisted thoracoscopySmall peripheral tumors (< 2 cm in diameter), pleural tumors, or pleural effusionsMay prevent the need for thoracotomy
ThoracotomyOnly clearly resectable tumorsRecommended for diagnosis and treatment of early non–small cell carcinoma

Several options are available when the type and stage of the cancer are less clear, including sputum cytology, flexible bronchoscopy, and transthoracic needle aspiration. Sputum cytology is a noninvasive test that may be useful in identifying centrally located tumors. The test detects 71 percent of central tumors but less than 50 percent of peripheral tumors27; therefore, further testing must follow a negative result.

Flexible bronchoscopy (employing bronchial washings, brushings, and biopsies) often is the test of choice in patients with central tumors, with a combined sensitivity of 88 percent in these patients.28 Despite the addition of fluoroscopic and computed tomography (CT) guided transbronchial needle aspiration, the sensitivity of bronchoscopy falls to 70 percent in patients with peripheral tumors and even lower in patients with a tumor less than 2 cm in diameter.28,29 Pneumothorax and bleeding are serious but uncommon complications of transbronchial needle aspiration.29

Transthoracic needle aspiration has been shown to be more sensitive than bronchoscopy in patients with peripheral lung tumors and may be used when transbronchial needle aspiration is inconclusive or in patients who are not surgical candidates.28 Transthoracic needle aspiration is routinely guided by fluoroscopy or CT, and the assistance of a cytopathologist increases the diagnostic yield. The most common complication of transthoracic needle aspiration is pneumothorax (25 to 30 percent), but the procedure rarely requires chest tube insertion.29

Video-assisted thoracoscopy is a newer modality that may be used to sample small peripheral tumors (less than 2 cm in diameter), pleural tumors, or pleural effusions for diagnostic or staging purposes.30

STAGING

After establishing a tissue diagnosis, a thorough staging work-up, including metastatic evaluation (Figure 127,2932 ) and staging classification, should be performed to determine the presence of metastasis and to identify surgical resection candidates.

Initial evaluation for metastasis can be performed by the primary care physician and includes a detailed history; physical examination; complete blood count; and levels of electrolyte, calcium, hepatic transaminases, and alkaline phosphatase. More than 80 percent of patients with an abnormality on evaluation have metastatic disease.31 Patients presenting with anorexia, weight loss, and fatigue have an especially poor prognosis.33

Noninvasive radiographic imaging with chest CT and positron emission tomography (PET) scans is routinely performed in patients with suspected metastatic lung cancer. Chest and upper abdomen CT scans may reveal hilar and mediastinal adenopathy and liver or adrenal involvement. Although CT accuracy is 88 percent (80 percent sensitive, 100 percent specific) in the mediastinum, staging is enhanced by PET.34 Integrated CT/PET scanners appear to have better test characteristics than CT or PET alone.35

In patients with suspected mediastinal disease, the remainder of the mediastinal staging evaluation usually is performed in consultation with subspecialists and may include bronchoscopy with or without transbronchial needle aspiration, endobronchial ultrasonography–guided transbronchial needle aspiration, transthoracic needle aspiration, video-assisted thoracoscopy, or mediastinoscopy. The clinical presentation dictates the use of additional staging measures. Abdominal CT, bone scanning, and brain magnetic resonance imaging are usually recommended in patients with small cell carcinoma because of the high likelihood of metastatic disease.

After the metastatic evaluation is complete, the staging classification (Table 436 ) can be determined based on the type of tumor identified and the presence or absence of metastatic disease. Non–small cell carcinoma is categorized using the TNM (tumor-nodes-metastasis) staging system, whereas small cell carcinoma is categorized as limited disease confined to the ipsilateral hemithorax or as extensive disease with metastasis beyond the ipsilateral hemithorax.16

StageDescription
Non–small cell carcinoma (TNM staging system)
Local
IA (T1N0M0)T1: 3 cm or less in diameter; surrounded by lung or pleura; does not invade main bronchus
IB (T2N0M0)T2: more than 3 cm in diameter; may invade pleura; may extend into main bronchus but remains 2 cm or more distal to carina; may cause segmental atelectasis or pneumonitis
IIA (T1N1M0)N1: involvement of ipsilateral peribronchial or hilar nodes and intrapulmonary nodes
Locally advanced
IIB (T2N1M0 and T3N0M0)T3: invasion of chest wall, diaphragm, pleura, or pericardium; main bronchus less than 2 cm distal to carina; atelectasis of entire lung
IIIA (T1N2M0, T2N2M0, T3N1M0, and T3N2M0)N2: involvement of ipsilateral mediastinal or subcarinal nodes
IIIB (T1-4N3M0)N3: involvement of contralateral nodes or any supraclavicular nodes
Advanced
IIIB (T4N1-3M0)T4: invasion of mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or carina; separate tumor nodules; malignant pleural effusion
IV (T1-4N1-3M1)Distant metastasis
Small cell carcinoma
LimitedDisease confined to the ipsilateral hemithorax
ExtensiveDisease with metastasis beyond the ipsilateral hemithorax

FUNCTIONAL EVALUATION

The final component of the diagnostic assessment is a functional evaluation of the patient. Evaluation of performance and pulmonary status should be completed before discussing treatment options. Pulmonary function testing, specifically forced expiratory volume in one second (FEV1) and carbon monoxide diffusion in the lung (DLCO) measurements, is a helpful predictor of morbidity and mortality in patients undergoing lung resection.15

Patients with an FEV1 or DLCO value less than 80 percent of predicted require additional testing. This includes calculation of postresection pulmonary reserve (with ventilation and perfusion scans or by accounting for the number of segments removed); cardiopulmonary exercise testing (with a maximum volume of oxygen utilization [VO2max] measurement); and arterial blood gas sampling (with an oxygen saturation in arterial blood [SaO2] measurement). Patients with a predicted postoperative FEV1 or DLCO value less than 40 percent and a VO2max value less than 10 mL per kg per minute or an SaO2 value less than 90 percent are at high risk of perioperative death or complications.36

Treatment and Prognosis

Treatment differs according to the histologic type of cancer, the stage at presentation, and the patient's functional evaluation (Table 536 ). Surgery is the treatment of choice for patients with stage I through IIIA non–small cell carcinoma.37 Recent data suggest that preoperative chemotherapy improves survival in patients with non–small cell carcinoma.38 For patients undergoing complete resection and no preoperative chemotherapy, adjuvant chemotherapy is standard. Randomized controlled clinical trials should address the issue of preoperative versus postoperative adjuvant treatment.38

StagePrimary treatmentAdjuvant therapyFive-year survival rate (%)
Non–small cell carcinoma
IResectionChemotherapy60 to 70
IIResectionChemotherapy with or without radiotherapy40 to 50
IIIA (resectable)Resection with or without preoperative chemotherapyChemotherapy with or without radiotherapy15 to 30
IIIA (unresectable) or IIIB (involvement of contralateral or supraclavicular lymph nodes)Chemotherapy with concurrent or subsequent radiotherapyNone10 to 20
IIIB (pleural effusion) or IVChemotherapy or resection of primary brain metastasis and primary T1 tumorNone10 to 15 (two-year survival)
Small cell carcinoma
Limited diseaseChemotherapy with concurrent radiotherapyNone15 to 25
Extensive diseaseChemotherapyNone< 5

Treatment for unresectable non–small cell carcinoma may involve radiotherapy and chemotherapy. The role of targeted therapies, specifically the antivascular endothelial growth factor agent bevacizumab (Avastin), has been examined in patients with advanced stage (IIIB and IV) nonsquamous carcinoma. Bevacizumab combined with chemotherapy increased survival compared with chemotherapy alone.39 Chemotherapy (combined with radiotherapy in limited stage disease) is the mainstay of treatment for small cell carcinoma.37

Palliative and hospice care are important end-of-life treatment modalities. The primary care physician can help patients determine what options may be most appropriate. Table 6 includes hospice and palliative care resources.

American Academy of Hospice and Palliative Medicine
Web site:http://www.aahpm.org
American Board of Hospice and Palliative Medicine
Web site:http://www.abhpm.org
American Pain Society
Web site:http://www.ampainsoc.org
Americans for Better Care of the Dying
Web site:http://www.abcd-caring.org
Approaching Death: Improving Care at the End of Life
Publisher: The National Academies Press
Before I Die: Medical Care and Personal Choices
Web site:http://www.wnet.org/bid/index.html
City of Hope Pain/Palliative Care Resource Center
Web site:http://www.cityofhope.org/prc
Dying Well: Defining Wellness Through the End of Life
Web site:http://www.dyingwell.org
End of Life/Palliative Education Resource Center
Web site:http://www.eperc.mcw.edu
EndLink Resource for End of Life Care Education
Web site:http://endlink.lurie.northwestern.edu

Screening

Although studies have assessed screening with sputum cytology, routine chest radiography, and low-dose CT, no study has demonstrated that screening improves survival, and no major organization currently endorses lung cancer screening.40 In 2004, the U.S. Preventive Services Task Force concluded that although there is fair evidence that screening may allow for earlier detection of lung cancer, there is poor evidence to suggest that any screening strategy decreases mortality.41 With no proven effect of screening on mortality rates, there is concern that screening may cause overdiagnoses and unnecessary anxiety, radiation exposure, and expense.42

Several large randomized controlled trials designed to evaluate the effect of screening on mortality are underway.43,44 Until these results become available, there is insufficient evidence to recommend for or against routine screening.

Prevention

Perhaps the primary care physician's most important role is preventing lung cancer by encouraging smoking cessation. The most effective cessation therapies (with quit rates ranging from 16 to 21 percent) are nicotine replacement, bupropion (Wellbutrin), nortriptyline (Pamelor), and structured telephone counseling.4553 Combining nicotine replacement, bupropion, and social or behavioral support can increase the quit rate to 35 percent.54 Informal counseling by physicians has also been shown to modestly increase quit rates.55,56

Continue Reading


More in AFP

Copyright © 2007 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See https://www.aafp.org/about/this-site/permissions.html for copyright questions and/or permission requests.